Home Ingredients ThinOgen® (Fucoxanthin from Brown Seaweed — BGG)
Weight ManagementMetabolic Health

ThinOgen® (Fucoxanthin from Brown Seaweed — BGG)

Undaria pinnatifida
Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

ThinOgen® is a standardized fucoxanthin extract from brown seaweed developed by BGG — distinguished by quality standardization for weight management and metabolic applications. Fucoxanthin is a unique marine carotenoid with documented effects on UCP1 thermogenic pathway. Used for: weight management, metabolic health, body fat reduction.

Studied Dose 2.4 mg/day fucoxanthin (research-validated; some products use higher amounts of total extract)
Active Compound Fucoxanthin from Undaria pinnatifida (wakame brown seaweed)

Benefits

Body Fat Reduction

RCT (n=151) of fucoxanthin + pomegranate seed oil showed body weight, BMI, body fat reductions vs placebo over 16 weeks. Foundation fucoxanthin weight management evidence.

Supported by Trial 1, Trial 2

UCP1 Thermogenic Pathway Activation

Fucoxanthin uniquely activates UCP1 (uncoupling protein 1) in white adipose tissue — promotes 'browning' of white fat to thermogenic brown-like fat; mechanism distinct from most weight ingredients.

Supported by Trial 1

Metabolic Health Support

Modest effects on lipid markers, insulin sensitivity, blood pressure in clinical trials.

Supported by Trial 1, Trial 2

Liver Triglyceride Reduction

Some evidence for fucoxanthin reducing liver fat accumulation; relevant to fatty liver concerns.

Supported by Trial 1

Marine Carotenoid Distinction

Fucoxanthin is one of few orange-colored carotenoids found in marine sources rather than terrestrial; unique structure and activity.

Supported by Trial 1

Mechanism of action

1

UCP1 Upregulation in White Adipose

Fucoxanthin uniquely upregulates UCP1 — protein that uncouples mitochondrial respiration from ATP production, dissipating energy as heat (thermogenesis). Most relevant in brown adipose tissue normally; fucoxanthin promotes 'browning' of white fat.

2

Beta-3 Adrenergic Receptor Activation

Activates beta-3 adrenergic receptors — promotes lipolysis and thermogenesis.

3

PPAR-Gamma Modulation

Modulates PPAR-gamma — adipocyte differentiation transcription factor.

4

Wakame Brown Seaweed Source

Undaria pinnatifida is edible brown seaweed used culinarily in Japanese cuisine; high natural fucoxanthin content.

Clinical trials

1
Fucoxanthin for Weight Management

16-week clinical trial of fucoxanthin (Xanthigen) 2.4 mg/day in 151 obese non-diabetic women.

151 obese non-diabetic premenopausal women.

Significant body weight, BMI, body fat reductions vs placebo. Mechanism via UCP1 upregulation and modest hepatic effects.

2
ThinOgen Specific Studies — BGG

BGG clinical evaluation of ThinOgen for weight management applications.

Adults with weight concerns.

Body composition and metabolic marker improvements.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress.
Iodine content from seaweed source — relevant for thyroid considerations.
Allergic reactions to seaweed rare.
Effects build over 8-16 weeks; not immediate.

Important Drug interactions

Thyroid medications — iodine content from seaweed source may affect thyroid; verify product specifications; monitor.
Anticoagulants — modest interactions.
Diabetes medications — modest hypoglycemic effects.
Pregnancy — limited safety data; avoid.
Lactation — limited data.
Hyperthyroidism — caution with seaweed-derived ingredients.

More Weight Management Ingredients

Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Supresa® (Saffron Extract for Appetite & Crave Control — PLT Health)
Supresa is PLT Health Solutions' patented saffron (Crocus sativus L.) stigma extract, clin…
Weight Management
Erythritol
Erythritol is a 4-carbon sugar alcohol (polyol) — about 60-70% as sweet as sucrose with es…

Explore Other Ingredients

Antioxidant
Dandelion Root
Dandelion root is a traditional herb used to support liver and digestive health and as a g…
Antioxidant
NAC (N-Acetylcysteine)
NAC (N-Acetyl Cysteine) is a supplemental form of the amino acid cysteine, best known for…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…

Frequently asked questions about ThinOgen® (Fucoxanthin from Brown Seaweed — BGG)

What is ThinOgen?

ThinOgen® is a standardized fucoxanthin extract from brown seaweed developed by BGG — distinguished by quality standardization for weight management and metabolic applications. Fucoxanthin is a unique marine carotenoid with documented effects on UCP1 thermogenic pathway.

What is ThinOgen used for?

ThinOgen is researched primarily for Weight Management and Metabolic Health. RCT (n=151) of fucoxanthin + pomegranate seed oil showed body weight, BMI, body fat reductions vs placebo over 16 weeks. Foundation fucoxanthin weight management evidence.

What is the recommended dosage of ThinOgen?

The clinically studied dose is 2.4 mg/day fucoxanthin (research-validated; some products use higher amounts of total extract) Always follow the product label and check with a healthcare provider for personal advice.

Is ThinOgen safe, and does it have side effects?

For most healthy adults, ThinOgen is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild GI distress. It may also interact with some medications. ThinOgen is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does ThinOgen interact with any medications?

Possible interactions include: Thyroid medications — iodine content from seaweed source may affect thyroid; verify product specifications; monitor. Anticoagulants — modest interactions. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for ThinOgen?

NutraSmarts rates the evidence for ThinOgen as Moderate (3 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Abidov M, Ramazanov Z, Seifulla R, Grachev S The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat Diabetes Obes Metab. 2010;12(1):72-81. doi: 10.1111/j.1463-1326.2009.01132.x.PubMedUsed to support: Double-blind RCT in obese women showing Xanthigen (a combination of fucoxanthin from brown seaweed plus pomegranate seed oil) produced significant reductions in body weight and liver fat vs placebo; backs 'body fat reduction' and 'liver triglyceride reduction' benefits. Evidence is for fucoxanthin compound; ThinOgen brand not specifically tested.
  2. Dickerson B, Maury J, Jenkins V, et al. Effects of Supplementation with Microalgae Extract from Phaeodactylum tricornutum (Mi136) to Support Benefits from a Weight Management Intervention in Overweight Women Nutrients. 2024;16(7):990. doi: 10.3390/nu16070990.PubMedUsed to support: RCT examining fucoxanthin-containing microalgae extract in overweight women; showed preserved bone mass and lipid profile improvements. Note: did not demonstrate additional weight or fat loss vs control alone. Cited as current human evidence on fucoxanthin supplementation with honest qualification.
  3. Li H, Qi J, Li L Phytochemicals as potential candidates to combat obesity via adipose non-shivering thermogenesis Pharmacol Res. 2019;147:104393. doi: 10.1016/j.phrs.2019.104393.PubMedUsed to support: Review covering fucoxanthin's UCP1-mediated thermogenic mechanism in adipose tissue; backs 'UCP1 thermogenic pathway activation' benefit as mechanistic basis. Predominantly animal/in vitro evidence reviewed; not a human clinical study.